Pharmacological Disruption of Glioblastoma Extracellular Vesicle-Myeloid Cell Interactions Mitigates Tumor-Induced Immunosuppression 2259453
The Journal of Immunology · 01.08.2026 · 215 (Supplement_1)
DOI: 10.1093/jimmun/vkag141.714 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 28.07.2026. Verfasst von Minori Aoki und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults, characterized by profound immunosuppression that hinders the effect of immunotherapies. Myeloid-derived suppressor cells (MDSCs), which dampen anti-tumor immune responses, are major contributors to this immunosuppression. GBM-derived extracellular vesicles (GBM-EVs) play a critical role in this process by promoting immunosuppressive polarization of myeloid cells. Therefore, targeting EV-myeloid cell interactions represents a novel target to mitigate GBM-mediated immune suppression. However, the precise mechanisms by which GBM-EVs induce an immunosuppressive effect on myeloid cells remain poorly understood.
Methods
Here, we utilize both in vitro and in vivo assays to determine the immunosuppressive functions of GBM-EVs and the effects of pharmacological inhibitors on disrupting the interaction between GBM-EVs and myeloid cells.
Results
Our data show that GBM-EV treatment significantly increases the monocytic MDSCs (mMDSCs) population in vitro (mean difference = 5.87 ± 1.77, 95% CI [2.17-9.56], p = 0.0017). In vivo, retro-orbital administration of EVs isolated from syngeneic murine glioma cell lines (SB28 and GL261) into C57BL/6 mice resulted in splenic contraction (p = 0.006, p = 0.026, respectively), and a profound increase in splenic mMDSCs (p = 0.0031) with SB28. To disrupt EV-myeloid interactions, we utilized two pharmacological agents targeting different mechanisms of EV uptake: methyl-β-cyclodextrin (MβCD) and cytochalasin D (CytoD). Our results showed that both treatments significantly reduced mMDSC frequency (CytoD: p = 0.023, MBCD: p = 0.0056) as well as the expression of immunosuppressive cytokines, including IL-10 (p = 0.045, 0.002) and TGF-β (p = 0.0068, 0.05).
Conclusion
These findings demonstrate that disrupting GBM-EV and myeloid cell interaction can rescue tumor-mediated immune suppression, providing a foundation for developing novel therapeutic strategies targeting EV-mediated immune suppression in GBM. Funding Source n/a Topic Categories Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
Zitieren
APA
Aoki, M., Asad, M., Baker, C., Himes, B., & Inocencio, J. (2026). Pharmacological Disruption of Glioblastoma Extracellular Vesicle-Myeloid Cell Interactions Mitigates Tumor-Induced Immunosuppression 2259453. The Journal of Immunology, 215(Supplement_1). https://doi.org/10.1093/jimmun/vkag141.714
Vancouver
Aoki M, Asad M, Baker C, Himes B, Inocencio J. Pharmacological Disruption of Glioblastoma Extracellular Vesicle-Myeloid Cell Interactions Mitigates Tumor-Induced Immunosuppression 2259453. The Journal of Immunology. 2026;215(Supplement_1). doi:10.1093/jimmun/vkag141.714
BibTeX
@article{Aoki2026,
author = {Aoki, Minori and Asad, Mohammad and Baker, Carolyn and Himes, Benjamin and Inocencio, Julio},
title = {Pharmacological Disruption of Glioblastoma Extracellular Vesicle-Myeloid Cell Interactions Mitigates Tumor-Induced Immunosuppression 2259453},
journal = {The Journal of Immunology},
year = {2026},
volume = {215},
number = {Supplement_1},
doi = {10.1093/jimmun/vkag141.714}
}
EUVIMED